NCT00921973已完成1 期
A Multicenter, Double-Blinded, Randomized, Placebo Controlled Study to Investigate the Safety and Immunogenicity of VAX102 When Given in the Same Arm With the Standard Influenza Vaccine in Healthy Adults
VaxInnate Corporation4 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2009年6月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
- 试验地点
- 4
- 主要终点
- Immune response
研究概览
简要总结
The study will assess the safety, reactogenicity, and tolerability of VAX102 when given with Trivalent Inactivated Influenza Vaccine (TIV) delivered in the same arm as two separate IM injections in healthy adults 18 to 49 years. The investigators will measure the immunogenicity of the VAX102 when given with TIV and the antibody response to TIV when given with VAX102 compared to TIV alone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 49 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female aged 18 - 49 years inclusive
- •Give written informed consent to participate in the study and adherence to all protocol requirements.
- •Healthy, as determined by medical history, physical examination, vital signs, and clinical safety laboratory examinations
- •Females willing to practice birth control during the study.
- •Women of childbearing potential must have a negative urine pregnancy test within 24 hours preceding receipt of vaccination.
- •Comprehension of the study requirements, expressed availability for the required study period, and ability to attend scheduled visits.
- •Did not receive influenza vaccination (TIV) during the 2008-2009 influenza season.
排除标准
- •Presence of significant acute or chronic, uncontrolled medical or psychiatric illness (institution of new medical or surgical treatment, or a significant dose alteration for uncontrolled symptoms or drug toxicity within 3 months) as determined by medical history and/or physical exam.
- •History of cancer.
- •History of impaired immunoresponsiveness, including diabetes.
- •Known hypersensitivity to a previous dose of influenza vaccine or allergy to eggs or any components of the study vaccines.
- •Received influenza vaccination during the 2008-2009 season
- •History of systemic hypersensitivity reactions to egg proteins, or any other component of FLUVIRIN®, or life-threatening reactions to previous influenza vaccinations.
- •Has known history of Guillain-Barré Syndrome
- •Presently receiving or history of receiving any medications or treatments that affects the immune system such as allergy shots, immune globulin, interferon, immunomodulators, cytotoxic drugs or drugs known to be frequently associated with significant major organ toxicity, or systemic corticosteroids (oral or injectable) in the past 6 months. Inhaled and topical corticosteroids will be allowed.
- •Participated in a clinical trial or received or planned administration of an investigational compound within 30 days before receiving study vaccine and/or during the study through the Day 28 evaluation.
- •Was vaccinated with a registered vaccine within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to receiving the study vaccine.
- •History of anaphylactic type reaction to injected vaccines.
- •History of drug or chemical abuse in the year before the study.
- •Use of new prescription medications started within 7 days before study entry.
- •Receipt of any blood products, including immunoglobulin, within 6 months before administration of study vaccine or anticipated receipt during the study period.
- •Donation of blood or blood products within 8 weeks before study entry or at any time during the study.
- •Has clinical signs of active infection and/or oral temperature of ≥ 38 (100.4 ºF). Study entry may be deferred for such individuals at the discretion of the investigator.
- •Has evidence or history of (within the previous 12 months) drug or alcohol abuse.
- •Any condition that, in the opinion of the investigator, might interfere with study objectives.
结局指标
主要结局
Immune response
时间窗: 2 months
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
终止
2 期
A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus InfectionChronic Hepatitis C Virus InfectionNCT01080222Vertex Pharmaceuticals Incorporated152
进行中（未招募）
2 期
VTX002 Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative ColitisColitis, UlcerativeNCT05156125Oppilan Pharma Ltd213
已完成
2 期
Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older AdultsPneumococcal VaccinesNCT05297578Vaxcyte, Inc.207
撤回
3 期
A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062)VaricellaNCT01626794Merck Sharp & Dohme LLC
已完成
2 期
Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe NailOnychomycosisNCT02343627Taro Pharmaceuticals USA47